{"Clinical Trial ID": "NCT00293540", "Intervention": ["INTERVENTION 1:", "Average Luteal Surgery", "[Unspecified]", "INTERVENTION 2:", "B Medium follicular surgery", "[Unspecified]"], "Eligibility": ["Incorporation criteria:", "Estrogen receptor or positive progesterone receptor breast cancer", "Premenopausal with regular menstrual cycles", "- Exclusion criteria:", "Current oral contraceptives"], "Results": ["Performance measures:", "Overall survival", "To assess whether patients undergoing surgical oophorectomy during the estimated average luteal phase of their menstrual cycle survive longer than patients undergoing surgery during the average follicular phase estimated by the history of their menstrual cycle.", "Time limit: up to 9 years", "Results 1:", "Title of arm/group: Middle luteal surgery", "Description of arm/group: [Unspecified]", "Total number of participants analysed: 115", "Median (95% confidence interval)", "Unit of measure: years 2.14 (1.53 to 2.67)", "Results 2:", "Title of arm/group: B Medium follicular surgery", "Description of arm/group: [Unspecified]", "Total number of participants analysed: 119", "Median (95% confidence interval)", "Unit of measure: years 2.00 (1.61 to 2.31)"], "Adverse Events": ["Undesirable Events 1:", "Total: 0/115 (0.00 per cent)", "Deep venous thrombosis * [1]0/115 (0.00 %)", "Adverse Events 2:", "Total: 1/119 (0.84%)", "Deep venous thrombosis * [1]1/119 (0.84%)"]}